Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Would you offer palliative radiation to a patient with hematuria from squamous metaplasia of the bladder that is not responding to endoscopic therapy?
If so, what dose would you use?
Answer from: Radiation Oncologist at Community Practice
No.
Sign In
or
Register
to read more
23171
Related Questions
What dose/fractionation would you recommend for a prostate patient who previously received 1 of 5 planned fractions SBRT in 2020?
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
Would you offer re-irradiation for a prostate local recurrence after I-125 seed implant >10 years ago in a healthy young patient with life expectancy >15 years?
In light of the recent data indicating increased late grade 3 to 5 toxicities (LTOX3) after hypofractionated salvage radiation therapy, will you continue to offer these regimes to patients?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
How would you manage a medically inoperable patient with locally recurrent nest variant muscle invasive urothelial carcinoma s/p radical cystectomy years ago now involving the urethral anastomosis, sphincter and neo-bladder, status post TUR?
What are the realistic, modern 10-year survival curves for localized prostate cancer given the improvements we have made in diagnostics and treatment?
Does long term use of 5 alpha reductase inhibitors change the way you evaluate a PSMA PET?